Effect of Peritransplant C3d Blockade and Ischemia on Chronic Rejection and Vasculopathy in an Experimental OMC Flap Model of VCA
Abstract
Based on observations that the complement protein C3d plays a pivotal role in the regulation of cell mediated immunity, we are hypothesizing that blockade of this protein early in the post-transplant period may mitigate rejection, and ischemia reperfusion injury (IRI). We are using our allogeneic rat VCA model to determine where C3d and its receptor CD21(also known as complement receptor 2 (CR2)) binds in the allograft, in models designed to mimic severe acute cellular rejection (ACR), mild ACR and chronic rejection (CR). Interestingly, C3d binds in ACR, and binds first to structures within the hair follicle in the skin as well as vessels. We have produced bulk antibody from a new J558L-CR2-IgG1 cell line (a gift from Dr. Steffen Thiel) and delivered the construct at the time on transplant for a group of chronic rejection animals. In the next year we plan to focus on assessing the distribution of C3d and CR2 expression and how those changes in relation to other immune markers as acute and chronic rejection develops in the several hundred tissue samples of our control groups and the treated animals. We will continue to culture and isolate the construct from the productive cell line.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1226216
Entities
People
- Christina Kaufman
Organizations
- University of Louisville